Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation

Trial Profile

Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 May 2018

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Apr 2018 Planned number of patients changed from 64 to 70.
    • 27 Apr 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
    • 27 Apr 2018 Planned primary completion date changed from 15 Apr 2018 to 29 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top